Clinical Trial Update: SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating stereotactic body radiotherapy (SBRT) in combination with ipilimumab and nivolumab for metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING